Literature DB >> 30591497

Influence of Neoadjuvant Chemotherapy on Short-term Outcomes After Minimally Invasive Esophagectomy for Esophageal Cancer.

Daichi Nomoto1, Naoya Yoshida1, Takahiko Akiyama1, Yuki Kiyozumi1, Kojiro Eto1, Yukiharu Hiyoshi1, Yohei Nagai1, Masaaki Iwatsuki1, Shiro Iwagami1, Yoshifumi Baba1, Yuji Miyamoto1, Hideo Baba2.   

Abstract

BACKGROUND/AIM: The safety of minimally invasive esophagectomy (MIE) after neoadjuvant chemotherapy (NAC) for esophageal cancer has not been adequately confirmed. PATIENTS AND METHODS: Two hundred and twelve patients who underwent MIE for esophageal cancer at the Kumamoto University Hospital between May 2011 and June 2018 were enrolled. A total of 46 patients received NAC and underwent subsequent MIE. The control group comprised 166 patients who underwent MIE without any preoperative treatments. We retrospectively investigated the patient-related, tumor-related, and surgery-related factors, as well as the short-term outcomes, between the two groups.
RESULTS: Preoperative lymphocyte counts and hemoglobin and albumin levels were significantly lower in the NAC plus MIE group than in the MIE alone group. Preoperative nutritional status, as measured by the prognostic nutrition index and controlling nutritional status, was also poorer in the NAC plus MIE group (p<0.001). However, short-term outcomes such as operation time, intraoperative blood loss, and incidence of postoperative complications were statistically equivalent between the groups.
CONCLUSION: Although administration of NAC was associated with a poorer preoperative condition, it did not worsen the short-term outcomes after MIE. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Esophageal cancer; esophagectomy; minimally invasive esophagectomy; neoadjuvant chemotherapy

Mesh:

Year:  2019        PMID: 30591497     DOI: 10.21873/anticanres.13136

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Effectiveness and safety of a newly introduced multidisciplinary perioperative enhanced recovery after surgery protocol for thoracic esophageal cancer surgery.

Authors:  Hiroshi Sato; Yutaka Miyawaki; Seigi Lee; Hirofumi Sugita; Shinichi Sakuramoto; Yasuhiro Tsubosa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2021-10-01

2.  Feasibility research of enhanced recovery after surgery implemented in esophageal cancer patients who underwent neoadjuvant chemotherapy.

Authors:  Zhanpeng Tang; Xirui Zhu; Yanzhi Li; Chenghao Qu; Lin Li; Shuhai Li; Lei Qi; Ming Lu; Chuanle Cheng; Hui Tian
Journal:  World J Surg Oncol       Date:  2022-07-25       Impact factor: 3.253

3.  The safety of neoadjuvant chemotherapy combined with non-tube nofasting fast-track surgery for esophageal carcinoma.

Authors:  Yan Zheng; Wentao Hao; Yin Li; Xianben Liu; Zongfei Wang; Haibo Sun; Shilei Liu; Wenqun Xing
Journal:  Front Oncol       Date:  2022-08-31       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.